Ozempic benefits research has made a major breakthrough in treating fatty liver disease. The Phase III ESSENCE trial showed that Ozempic (semaglutide), a medication used for type 2 diabetes and obesity, improves outcomes for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe form of fatty liver disease.Moreover, This trial marks a significant advancement in treating liver conditions that have been difficult to manage.

Ozempic Benefits Research: Shows Promise in Treating Liver Disease

The Ozempic benefits research was published in the New England Journal of Medicine.In addition, The trial conducted across 253 sites in 37 countries proved that Ozempic could halt and reverse liver damage from MASH. Experts Professor Philip Newsome of King’s College London and Professor Arun Sanyal of Virginia Commonwealth University led the study.

https://whatshappening.pk/apple-phone-prices-update-iphone-costs-may-rise-says-wsj/

The Phase III trial is the first to show that a treatment like Ozempic can improve liver outcomes.However, this offers hope for millions, as no medications are currently licensed to treat MASH.

Ozempic Benefits Research: How it Improves Liver Function

In the ESSENCE trial, over 800 patients received Ozempic injections (2.4 mg) weekly for 72 weeks. They also received lifestyle counseling. The results were promising. 62.9% of patients on Ozempic showed reduced liver inflammation. Only 34.3% of patients on the placebo showed similar improvement.

Moreover the trial also showed improvement in liver fibrosis. 36.8% of patients on Ozempic showed improvement, compared to 22.4% in the placebo group. These results highlight Ozempic’s effectiveness in treating fatty liver disease.

Ozempic’s Effect on Obesity and Type 2 Diabetes Patients

The study group included individuals with obesity (75%) and type 2 diabetes (50%). Ozempic not only improved liver function but also led to significant weight loss. Patients on Ozempic showed improvements in liver enzymes. These enzymes are often elevated in fatty liver disease.

However, Ozempic caused more gastrointestinal side effects such as nausea and diarrhea in the treatment group. Despite this, the overall benefits for liver health make Ozempic a promising option.

The Future of Ozempic in Liver Disease Treatment

MASH and its broader condition, MASLD, affect millions worldwide. Ozempic benefits research offers hope for treating these diseases. In addition,The research team plans to monitor 1,200 patients for the next five years to assess Ozempic’s long-term benefits and safety in liver disease treatment.

Conclusion

The Ozempic benefits research marks a significant advancement in treating fatty liver disease. It shows Ozempic’s potential in improving liver inflammation and fibrosis. As more studies continue, Ozempic may become a key therapy for MASH and MASLD, offering a breakthrough in liver disease management.

STAY UPDATED WITH THE LATEST NEWS. FOLLOW US ON OUR SOCIAL MEDIA CHANNELS:

INSTAGRAM: https://www.instagram.com/whatshappening.pk

FACEBOOK: http://www.facebook.com/whatshappening.pk